Table 1 Baseline and study end anthropometric and biochemical parameters for diabetic (db/db) and non-diabetic (db/m) mice.

From: Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes

 

Control

Diabetes

DMitoQ

DRam

DCoAd

At study commencement

Body wt (g)

25.4 ± 1.5

39.1 ± 1.4*

37.2 ± 2.5*

36.2 ± 2.5*

40.0 ± 1.8*

FBG (mmol/L)

9.1 ± 2.6

23.8 ± 4.8*

29.3 ± 7.0*

22.2 ± 4.1*

24.5 ± 4.5*

GHb (%)

5.7 ± 1.9

7.8 ± 2.5*

7.4 ± 1.6*

6.7 ± 2.9*

7.0 ± 1.9*

At study end

Kidney weight (mg/mm tibial length)

14.8 ± 1.4

20.8 ± 2.1*

19.8 ± 3.7*

20.1 ± 2.7*

22.2 ± 2.3*

Food consumption (g/24 h)

5.3 ± 1.1

9.7 ± 2.2*

8.4 ± 2.9*

9.8 ± 1.5*

9.8 ± 3.1*

Water consumption (ml/24 h)

4.1 ± 0.9

21.2 ± 6.3*

19.7 ± 9.3*

23.3 ± 6.5*

24.0 ± 7.5*

Urine output (ml/24 h)

0.4 ± 0.3

15.7 ± 7.8*

13.1 ± 7.1*

16.1 ± 7.6*

17.9 ± 9.6*

  1. Non-diabetic db/m mice (Control); Diabetic db/db mice (Diabetes); Diabetic db/db mice + 0.6 mg/kg/day MitoQ orally (DMitoQ); Diabetic db/db mice + 3 mg/kg/day Ramipril orally (DRam); Diabetic + 0.6 mg/kg/day MitoQ orally (DMitoQ) + 3 mg/kg/day Ramipril orally (DCoAd); Grey bars/dots − diabetic db/db mice + combination of MitoQ and Ramipril (DCoAd). n = 6–13 mice/group. FBG – fasting blood glucose; GHb – glycated haemoglobin; KW – kidney weight. Data expressed as Mean ± SEM apart from Body wt and KW. *P < 0.05 vs C by 1 W ANOVA/Tukey’s Post-hoc.
Back to article page